BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits 
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
SAN DIEGO, March 27, 2017 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, today announced that TRC694 preclinical data will be presented at the upcoming American Association for Cancer Research (AACR) annual meeting to be held April 1-5, 2017, in Washington, D.C.
Lut Janssen and colleagues from Janssen Research & Development will present a poster featuring data from preclinical studies of TRC694. The presentation details are as follows:
| Abstract Number: | 4199 |
| Abstract Title: | Inhibition of NF-kB inducing kinase (NIK) selectively abrogates NIK and TRAF3 mutant multiple myeloma tumor growth |
| Session Category: | Experimental and Molecular Therapeutics |
| Location: | Section 7, Poster Board Number 22 |
| Date: | Tuesday, April 4, 2017 |
| Time: | 1:00pm – 5:00pm EDT |
The poster will be available on the Company’s website.
About TRC694
TRC694 is a novel, potent, orally bioavailable inhibitor of NF-kB inducing kinase (NIK) with the potential to be first-in-class that was discovered by Janssen and licensed by TRACON in September 2016. In pre-clinical studies, TRC694 selectively repressed P52/RelB mediated non-canonical NF-kB gene expression and inhibited NIK and TRAF3 mutant cell line proliferation in vitro and tumor growth in vivo. Genetic alterations leading to stabilization of NIK are found in a subset of B-cell malignancies: multiple myeloma, mantle-cell lymphoma (where it is associated with ibrutinib resistance), diffuse large B-cell lymphoma, Hodgkin’s lymphoma, and chronic lymphocytic leukemia.
About TRACON
TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
Company Contact: Casey Logan Chief Business Officer (858) 550‐0780 ext. 236 [email protected] Investor Contact: Andrew McDonald LifeSci Advisors LLC 646-597-6987 [email protected]
